Nanobiotix SA (XPAR:NANO)

€ 4.86 -0.122 (-2.45%) Market Cap: 230.39 Mil Enterprise Value: 205.67 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

Q1 2024 Nanobiotix SA Earnings Call Transcript
May 22, 2024

€5.7 (-12.44%)

Earnings
Nanobiotix SA 65th ASTRO Annual Meeting 2023 Transcript
Oct 05, 2023
Half Year 2023 Nanobiotix SA Earnings Call Transcript
Sep 27, 2023

€8.2 (+0.49%)

Earnings
Nanobiotix SA at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Nanobiotix SA License Agreement with Janssen Briefing Transcript
Jul 10, 2023
Q4 2022 Nanobiotix SA Earnings Call Transcript
Apr 25, 2023

€2.4 (-31.47%)

Earnings
Nanobiotix SA at Evercore ISI HealthCONx Conference (Virtual) Transcript
Dec 01, 2022
Nanobiotix SA at Jefferies London Healthcare Conference Transcript
Nov 15, 2022
Q3 2022 Nanobiotix SA Earnings Call Transcript
Nov 10, 2022

€3.7 (+1.51%)

Earnings
Q2 2022 Nanobiotix SA Earnings Call Transcript
Sep 29, 2022

€3.59 (-0.28%)

Earnings
Nanobiotix SA at UBS Global Healthcare Conference Transcript
May 23, 2022
Q1 2022 Nanobiotix SA Earnings Call Transcript
May 19, 2022

€5.35 (+3.08%)

Earnings
Q4 2021 Nanobiotix SA Earnings Call Transcript
Mar 31, 2022

€6.64 (-2.64%)

Earnings

Nanobiotix SA at UBS Global Healthcare Conference Transcript

May 23, 2022 / 02:45PM GMT

Release Date Price: €5.2 (+1.17%)

Transcript

Colin Bristow

UBS - Managing Director, Biotechnology

Good morning, everyone, and thank you for attending the UBS Global Healthcare Conference. I'm Colin Bristow, one of the biotech analysts at UBS. It's my pleasure to have with us Laurent Levy, CEO of Nanobiotix; and Bart Van Rhijn, CFO of Nanobiotix. Thank you.

(Conference Instructions) So Laurent and Bart, thank you very much for coming today. And I know you have a few points you wanted to relay before we get into questions. So I'll hand it over to you.

Laurent Levy

Nanobiotix SA - CEO

Sure. Thank you, Colin. We will be happy to start this chat by telling you a bit more about the company and the technology we are developing. And just maybe starting by the way we look at cancer. We felt that if we bring something really new in cancer treatment, we should not follow others' paths. So we should bring something new for the patients and their family.

So we looked at everything that is out there including chemistry and biology as one of the main stream of the treatment and felt that they bring

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.